ABL1, SRC and other non-receptor tyrosine-kinases as new targets for specific anticancer therapy

Abstract

Aberrant activity of protein tyrosine kinases has been implicated in the stimulation of cancer growth. Small molecule tyrosine kinase imhibitors interfere with this pathological circuits and thus belong to promissing anticancer agents.

Keywords

• non-receptor tyrosine kinases
• SRC
• BCR
• ABL1
• TKI
• imatinib
• nilotinib
• dasatinib
• CML
• solid tumours
• prostate cancer
• bone metastases